EUVIMEDOdkrijte EUVIMED
Mixed-Methods-StudieStudienprotokollOpen access

Development and Validation of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS): Protocol for an International Multistage Mixed Methods Study

Philip A Powell iD, Anju Keetharuth iD, Sé Maria Frances iD, Jill Carlton iD, Kelly Makarounas-Kirchmann iD, Antonio Adolfo Guerra Soares Brandão iD, Karthik Ramasamy iD, Francis Shupo iD, Kelley C Dacus iD, Corey Casper iD, David C Fajgenbaum iD, Yeow Goh iD and 5 more

JMIR Research Protocols · 2026-08-11 · 15 · e96022

DOI: 10.2196/96022 ↗

At a glance

Mixed-Methods-Studie in JMIR Research Protocols, published online on 2026-08-11. Written by Philip A Powell and 16 co-authors. Institution: School of Medicine and Population Health, University of Sheffield, Sheffield, England, United Kingdom. Major MEDLINE topics: Castleman Disease, Patient Reported Outcome Measures. 67 references. The full text is freely available in PubMed Central.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Background

Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder that is associated with a broad range of symptoms, including constitutional, gastrointestinal, neuropsychiatric, dermatologic, respiratory, and hematologic or lymphoreticular problems. These broad symptoms can impact the daily lives of people living with iMCD, creating a high symptom burden. Despite this, no robust, disease-specific patient-reported outcome measure (PROM) for subjective iMCD symptom burden exists. This limits accurate symptom monitoring, impacts sensitive end point selection in clinical trials, and represents a regulatory gap in patient-centered evidence generation when evaluating iMCD treatments.

Objective

This protocol describes the international multistakeholder Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS) project. The primary aim of this project is to develop and preliminarily evaluate the measurement properties of a novel PROM for capturing symptom burden (ie, perceived symptom frequency and impact on daily life) in people living with iMCD. The central objective is to produce a valid and robust PROM that can be used to assess iMCD symptom burden in research, clinical trials, and symptom monitoring in clinical practice.

Methods

The project has a mixed methods design, split into 4 sequential stages, with collaborative advisory input throughout. Stage 1 uses existing data and consultation with expert clinical and patient advisors to generate draft PROM content. Stage 2 uses qualitative cognitive debriefing interviews (n=10) to evaluate the content validity of the draft PROM content and enable meaningful revisions. Stage 3 involves a cross-sectional quantitative survey design in people living with iMCD (n≥50), allowing for psychometric analyses of structural validity (using classical test theory and/or Rasch methodology), construct validity (known-group validity and correlational methods), and internal consistency reliability (Cronbach α). Stage 4 uses a mixed methods design, including longitudinal quantitative survey evidence (n≥20) and qualitative interviews (n=10), triangulated to estimate preliminary meaningful change estimates for the new PROM. The project is international in scope, with primary data collection in 6 countries (ie, Australia, Brazil, Canada, New Zealand, the United Kingdom, and the United States).

Results

Funding for ISBUS began in June 2023 and is ongoing. As of March 2026, stage 3 had been completed, with 51 people living with iMCD completing the survey, and stage 4 was ongoing, with 32 follow-up surveys completed. Analyses for stages 1-3 were completed and are expected to be published in 2026, followed by stage 4 findings in 2027.

Conclusions

The aim of the ISBUS project is to produce a novel symptom burden PROM codeveloped with patients with iMCD to measure what matters to patients with iMCD. It is anticipated that the new PROM will be used in iMCD research, as a secondary end point in trials, and as a clinical tool to monitor symptom burden in the management of iMCD. Trial Registration ClinicalTrials.gov NCT05995834; https://clinicaltrials.gov/study/NCT05995834 International Registered Report Identifier (IRRID) DERR1-10.2196/96022

Subjects

MeSH terms (MEDLINE)

Castleman DiseasePatient Reported Outcome MeasuresHumansPsychometricsQuality of LifeReproducibility of ResultsSurveys and QuestionnairesSymptom BurdenObservational Studies as Topic

Author keywords

COAPROMclinical outcome assessmentiMCDidiopathic multicentric Castleman diseasemeaningful changeminimal clinically important difference, patient-centered outcomepatient-reported outcome measurepsychometricsqualitative researchsymptom burden

Authors and institutions

  • School of Medicine and Population Health, University of Sheffield, Sheffield, England, United Kingdom.
  • KMC Health Care, Melbourne, Australia.
  • Hospital BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom.
  • Oxford University Hospitals NHS Trust, Oxford, England, United Kingdom.
  • Recordati Rare Diseases, Hemel Hempstead, England, United Kingdom.

ORCID profiles: Philip A Powell, Anju Keetharuth, Sé Maria Frances, Jill Carlton, Kelly Makarounas-Kirchmann, Antonio Adolfo Guerra Soares Brandão, Karthik Ramasamy, Francis Shupo, Kelley C Dacus, Corey Casper, David C Fajgenbaum, Yeow Goh, Frits van Rhee, Pier Luigi Zinzani, Éric Oksenhendler, Lu Zhang, Sudipto Mukherjee

Cite

APA

Powell, P. A., Keetharuth, A., Frances, S. M., Carlton, J., Makarounas-Kirchmann, K., Guerra Soares Brandão, A. A., Ramasamy, K., Shupo, F., Dacus, K. C., Casper, C., Fajgenbaum, D. C., Goh, Y., van Rhee, F., Zinzani, P. L., Oksenhendler, É., Zhang, L., & Mukherjee, S. (2026). Development and Validation of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS): Protocol for an International Multistage Mixed Methods Study. JMIR Research Protocols, 15, e96022. https://doi.org/10.2196/96022

Vancouver

Powell PA, Keetharuth A, Frances SM, Carlton J, Makarounas-Kirchmann K, Guerra Soares Brandão AA, et al. Development and Validation of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS): Protocol for an International Multistage Mixed Methods Study. JMIR Research Protocols. 2026;15:e96022. doi:10.2196/96022

BibTeX
@article{Powell2026,
  author = {Powell, Philip A and Keetharuth, Anju and Frances, Sé Maria and Carlton, Jill and Makarounas-Kirchmann, Kelly and Guerra Soares Brandão, Antonio Adolfo and Ramasamy, Karthik and Shupo, Francis and Dacus, Kelley C and Casper, Corey and Fajgenbaum, David C and Goh, Yeow and van Rhee, Frits and Zinzani, Pier Luigi and Oksenhendler, Éric and Zhang, Lu and Mukherjee, Sudipto},
  title = {Development and Validation of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS): Protocol for an International Multistage Mixed Methods Study},
  journal = {JMIR Research Protocols},
  year = {2026},
  volume = {15},
  pages = {e96022},
  doi = {10.2196/96022}
}
Start for free →